TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02425852
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine alone versus Azathioprine and IFX
Study: NCT03066466
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV medication given to prevent graft versus host disease in bone marrow transplant.
Study: NCT02425852
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02425852
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04125082
Drug: Afrezza Inhalant Product
Normalized name: Afrezza Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be titrated from usual pre-meal insulin plus basal to Afrezza® inhaled insulin plus basal, and will continue on treatment for 14 weeks.
Study: NCT00251680
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
Study: NCT05820880
Drug: Fixed [Per/Ind/Aml]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed Dose combination of Perindopril/Indapamide/Amlodipine
Study: NCT03007225
Drug: TACE with Drug Eluting Beads procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The same was done as cTACE till the super selective catheterization of the feeding artery.~Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan).
Study: NCT01413204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive Placebo orally for 24 weeks.
Study: NCT02978781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 matching placebo capsules
Study: NCT01796366
Drug: insulin 338 (GIPET I)
Normalized name: insulin isophane, human Injectable Suspension [Humulin I]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
Study: NCT01796366
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: S.c placebo administered in combination with insulin 338
Study: NCT01796366
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo administered in combination with s.c. insulin glargine
Study: NCT00521404
Drug: CS-1008 (humanized anti-DR5 antibody)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
Study: NCT00711191
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine 1000 mg/m\^2 intravenous administration \[IV\] q week \[wk\]x3 of 4-week cycles
Study: NCT00739830
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
Study: NCT02035267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection.
Study: NCT01045837
Drug: Prednisolone and Gluten free diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
Study: NCT03038880
Drug: Sham Procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The sham was a procedure that mimicked an IVT injection and involved the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It was administered to participants in the faricimab treatments arms at applicable visits to maintain masking among treatment arms.
Study: NCT01817803
Drug: furosemide/no spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: furosemide (doubling previous furosemide dose)
Study: NCT01817803
Drug: metolazone/no spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: metolazone (add 2.5mg qod)
Study: NCT01817803
Drug: furosemid/spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
Study: NCT01817803
Drug: metolazone/spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
Study: NCT02376699
Drug: Intravenous (IV) SEA-CD40
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravenously; schedule is cohort-specific.
Study: NCT02376699
Drug: Subcutaneous (SC) SEA-CD40
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given subcutaneously on Day 1 every 3 weeks
Study: NCT00404222
Drug: Hydrocodone/Acetaminophen Extended-Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets x 1
Study: NCT00404222
Drug: Hydrocodone/Acetaminophen Immediate Release (NORCO®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet q 4 hours x 3
Study: NCT00404222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: q 4 hours x 3
Study: NCT01672671
Drug: Doxorubicin, Paclitaxel, Cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
Study: NCT01730222
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine at 1250 mg/ m2 days 1-28
Study: NCT01537705
Drug: Neuron012703 (Medical Food)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules twice daily for sixty days.
Study: NCT01318460
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty-four hour administration of placebo
Study: NCT04085289
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01364844
Drug: DS-7423
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
Study: NCT00176917
Drug: Busulfan, Cyclophosphamide, ATG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Study: NCT03849508
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg
Study: NCT02577718
Drug: Nitroglycerin-citrate-ethanol (NiCE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
Study: NCT02812862
Drug: Spiolto® Respimat® (Tiotropium / Olodaterol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent.
Study: NCT02561832
Drug: Anthracycline
Normalized name: Anthracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
Study: NCT02561832
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
Study: NCT00499083
Drug: aromatase inhibition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
Study: NCT00499083
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV day 1 every 2 weeks for 4 cycles
Study: NCT00499083
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV day 1 every 2 weeks for 4 cycles
Study: NCT02567578
Drug: YH12852 0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02567578
Drug: YH12852 0.25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02567578
Drug: YH12852 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02567578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02222948
Drug: Placebo (for Vatelizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT04238364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Tablet(s)
Study: NCT00252668
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02283827
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02283827
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01680471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Study: NCT01174719
Drug: volume replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylstarch up to 50mL/kg/24 hrs
Study: NCT01174719
Drug: Humanalbumin 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanalbumin 5% up to 50 mL/kg/24 hours
Study: NCT01174719
Drug: volume replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: up 10 50mL/kg/24 hours
Study: NCT00663091
Drug: Bacteriophage
Normalized name: bacteriophages
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Study: NCT00663091
Drug: WPP-201 Bacteriophage
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Study: NCT00663091
Drug: Bacteriophages
Normalized name: bacteriophages
Approvals — FDA: no, EMA: no, PMDA: no
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Study: NCT01855594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet, 6 week course of oral administration
Study: NCT00060840
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 ppm of Nitric Oxide continuously administered for 48 hours
Study: NCT00976560
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
Study: NCT04623632
Drug: Transversus abdominus plane placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection of 40 ml of normal saline in the transversus abdominus plane
Study: NCT04472832
Drug: Placebo for Treatment A
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 tablets matched to mitapivat tablet
Study: NCT04472832
Drug: Placebo for Treatment B
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets matched to mitapivat tablet
Study: NCT04472832
Drug: Placebo for Treatment C
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets matched to mitapivat tablet
Study: NCT00151775
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts A, B, C: placebo, once daily
Study: NCT03983811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive 4 cycles of platinum-based doublet chemotherapy on day 1 with intercalated placebo (D8-15) every 3 weeks, and continued placebo for 2 years or until the occurrence of disease relapse, metastasis or unacceptable toxicity
Study: NCT01301027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill a day for 26 weeks
Study: NCT00080236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00074490
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Study: NCT00074490
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Study: NCT02389621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets for oral administration
Study: NCT03039686
Drug: RO7239361
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take RO7239361 subcutaneously on specified days over a 48 week blinded period
Study: NCT00997308
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, oral, for 4 weeks
Study: NCT00997308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03039686
Drug: Placebo for RO7239361
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take placebo subcutaneously on specified days over a 48 week blinded period
Study: NCT00067002
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg by vein on Day -6.
Study: NCT00717808
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
Study: NCT00002630
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03614156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (prefilled syringe, weekly IV administration)
Study: NCT03980704
Drug: resource protein
Normalized name: Resource Protein Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral high-protein oral supplement
Study: NCT02407600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01587924
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet
Study: NCT01286051
Drug: Follistim administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: adminstation of FSH for ovulation induction
Study: NCT02447302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653599
Drug: TTP273
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002618
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002618
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002618
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002618
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03783715
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
Study: NCT00870519
Drug: I-123-MNI-168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Study: NCT00870519
Drug: 123-I MNI-168
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Study: NCT02052999
Drug: Rozex gel 0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received topical Rozex gel 0.75% twice daily for 8 weeks
Study: NCT03200080
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2, 4, 6 or 8 Tozadenant matching placebo tablets
Study: NCT02452008
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
Study: NCT03200080
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
Study: NCT02665832
Drug: DWJ1351
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02665832
Drug: Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
Normalized name: rosuvastatin Oral Tablet [Crestor]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03500224
Drug: [14C]-TAK-954
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]-TAK-954 intravenous infusion.
Study: NCT00909298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03699215
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
Study: NCT00249899
Drug: Stable statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
Study: NCT00583076
Drug: AST-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
Study: NCT02352831
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00742404
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03686085
Drug: Dinoprostone 3 mg
Normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
Study: NCT03686085
Drug: placebo vaginal tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Study: NCT01298362
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no